BHVN

Biohaven Ltd. (BHVN) | Rumor.io

Biohaven

BHVN

Attention (50-day avg)0%

Attention rank (50-day avg)#860

Bullish sentiment (50-day avg)82%

Price to earnings ratio-1.93

Market capitalization2B

Earnings per share-4.55

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-738.8M

Social

What share of all stock conversation is about BHVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% -0.01	0% +0	0% +0

Sep 18

Biohaven Ltd. (BHVN) stock price increased by 15.6% on September 17, 2026, with a strong buying interest, but profit-taking led to a close below the intraday high.
A potential best-in-class asset, BHVN's epilepsy indication may benefit from a competitor's setbacks, with the topline results from the P2/3 Op trial expected in H2 2026.
The FDA hold on BHVN's deal with SK may be manageable, and the setback of a competitor, XENE, could have sent BHVN's stock price upward, even with the same mechanism of action.

Generated by AI

Sentiment

Of the messages about BHVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +3.03	84.94% +23.75	78.69% -2.21
Bearish	—	0% -3.03	15.06% -23.75	21.31% +2.21

Bullish· Aug 26

The company has secured a licensing deal for its Kv7 platform, featuring Phase 2/3 focal epilepsy asset opakalim, with SK Biopharmaceuticals for $400 million in immediate capital and a total package reaching $795 million in upfront and milestone incentives plus royalties.
The deal solves the company's short-term cash issue, allowing it to advance its pipeline and reduce the risk of dilution, with significant royalties offering further cash for the pipeline.
The company's elite management team, comprised of prestigious and impressive minds from a Yale spinoff, has successfully licensed its drugs, proving market potential for each asset, and has multiple major catalysts ahead, including a major readout in October.

Bearish· Dec 26

$BHVN's Phase 2 trial for BHV-7000 in major depressive disorder failed to meet its primary endpoint, sparking a significant decline in the stock's price.
The trial failure and resulting stock drop have led to a concentrated bearish setup, with a short float of 15.31% and a short ratio of 4.57, indicating elevated bearish positioning among investors.
Despite the stock's 70%+ year-to-date decline and recent downtrend, analysts still lean bullish, with 11 out of 18 analysts maintaining a Strong Buy rating and an average price target of $19.80, but options data suggest a bearish reality may be catching up.

Generated by AI

Topics

Of the messages about BHVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	91.67%	80.95%	3.84%
Technical Analysis	—	8.33%	10.54%	0.6%
Analysts	—	0%	1.7%	43.64%
Earnings	—	0%	4.08%	0.18%
Controversies	—	0%	2.72%	0.16%
Macro	—	0%	0%	51.57%

Earnings· Feb 25

Biohaven Pharmaceuticals ($BHVN) reported a Q4 loss of $2.32 per share, missing estimates by $0.39.
Revenue of $190.01M was up 441.1% year/year, beating consensus estimates.
The company had approximately $1.0 billion of available liquidity at the start of 2022.

Analysts· Sep 12

Biohaven Pharmaceutical's ($BHVN) price target was raised to $65 by Piper Jaffray analyst Tyler Van Buren, citing higher conviction in migraine treatments.
Morgan Stanley maintained its "Overweight" rating on Biohaven Pharmaceutical ($BHVN) with a target price of $45 per share.
Cantor Fitzgerald analysts set a price target of $57.00 for Biohaven Pharmaceutical ($BHVN), while Needham & Company LLC assigned a buy rating.

Announcements· Sep 10

Biohaven Ltd.'s ($BHVN) experimental epilepsy drug opakalim has been placed on partial clinical hold by the FDA due to findings in rodent studies.
The FDA has paused new patient enrollment in the RISE2 study, while existing patients can continue treatment, and a pivotal readout is still on track for H2 2026.
The hold is pending additional nonclinical data concerning a metabolite, and Biohaven's stock price has fallen significantly in response to the news.

Generated by AI

Community

Of the messages about BHVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	63.54%	77.63%
Newcomers	—	0%	36.46%	22.37%

Regulars· Sep 17

Biohaven's leadership has explicitly stated that they are benchmarking their anti-myostatin drug, taldefgrobep alfa, against Eli Lilly's bimagrumab efficacy profile, aiming to meet or beat established parameters for reducing body fat and increasing lean muscle mass.
Xenon's setback in psychiatry due to neuropsychiatric adverse events has effectively leveled the playing field with Biohaven in the depression market, as both companies have hit a wall in psychiatry.
If Biohaven can resolve its minor regulatory hurdle regarding rodent metabolites and present clean Phase 2/3 RISE3 data, it can position opakalim as the best-in-class alternative to Xenon's first-in-class drug, securing a massive, highly profitable cut of every dollar generated in the epilepsy market.

Newcomers· Sep 10

The FDA has placed a partial clinical hold on Biohaven's experimental epilepsy drug, opakalim, due to adverse findings in rodent studies, pausing new patient enrollment in trials.
The hold is a setback for Biohaven, which had been making progress with its epilepsy treatment and had recently received a $400 million upfront payment from SK Biopharmaceuticals for its Kv7 platform.
The hold has caused a significant decline in Biohaven's stock price, with shares falling over 13% in premarket trading and over 17% in some reports, raising concerns about the company's prospects and the potential impact on its ongoing trials.

Generated by AI

Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is how that market value lines up against the company’s book value relative to the broader pharmaceuticals and biotech industry. Over the past 3 years, Biohaven shareholders have seen the stock decline about 49.3%, which puts the focus squarely on whether its...

4d agoYahoo Finance

Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says

Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program a

11d agoYahoo Finance

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

18d agoMorningstar

Biohaven’s epilepsy drug hit with FDA clinical hold

Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.

19d agoYahoo Finance

Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN)

19d agoSeeking Alpha

Also Discussed

Investors talking about BHVN also mention

#	Name	Attention
1	uniQure N.V.QURE	0.02%+0.01
2	BPMC - Blueprint Medicines Corporation	——
3	Regenxbio Inc.RGNX	0%+0
4	SWTX - SpringWorks Therapeutics, Inc.	——
5	Crinetics Pharmaceuticals IncCRNX	0%0
6	Wave Life Sciences Ltd.WVE	0%+0
7	Edgewise Therapeutics Inc.EWTX	0%new
8	Vaxcyte Inc.PCVX	0%0
9	argenx SE American Depositary ReceiptARGX	0%0
10	Replimune Group, Inc.REPL	0%0

Biohaven Ltd.

Healthcare
Biotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications. Biohaven uses multiple proprietary development platforms, including approaches such as ion channel modulation, extracellular protein degradation, and antibody-drug conjugates, to build a diversified pipeline of investigational medicines. Headquartered in New Haven, Connecticut, Biohaven serves as a research-driven biopharmaceutical platform centered on advancing novel treatments across both common and underserved disease areas.

Website

Location

215 Church Street

New Haven, CT, 06510

United States

Social

What share of all stock conversation is about BHVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% -0.01	0% +0	0% +0

Sep 18

Biohaven Ltd. (BHVN) stock price increased by 15.6% on September 17, 2026, with a strong buying interest, but profit-taking led to a close below the intraday high.
A potential best-in-class asset, BHVN's epilepsy indication may benefit from a competitor's setbacks, with the topline results from the P2/3 Op trial expected in H2 2026.
The FDA hold on BHVN's deal with SK may be manageable, and the setback of a competitor, XENE, could have sent BHVN's stock price upward, even with the same mechanism of action.

Generated by AI

Sentiment

Of the messages about BHVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +3.03	84.94% +23.75	78.69% -2.21
Bearish	—	0% -3.03	15.06% -23.75	21.31% +2.21

Bullish· Aug 26

The company has secured a licensing deal for its Kv7 platform, featuring Phase 2/3 focal epilepsy asset opakalim, with SK Biopharmaceuticals for $400 million in immediate capital and a total package reaching $795 million in upfront and milestone incentives plus royalties.
The deal solves the company's short-term cash issue, allowing it to advance its pipeline and reduce the risk of dilution, with significant royalties offering further cash for the pipeline.
The company's elite management team, comprised of prestigious and impressive minds from a Yale spinoff, has successfully licensed its drugs, proving market potential for each asset, and has multiple major catalysts ahead, including a major readout in October.

Bearish· Dec 26

$BHVN's Phase 2 trial for BHV-7000 in major depressive disorder failed to meet its primary endpoint, sparking a significant decline in the stock's price.
The trial failure and resulting stock drop have led to a concentrated bearish setup, with a short float of 15.31% and a short ratio of 4.57, indicating elevated bearish positioning among investors.
Despite the stock's 70%+ year-to-date decline and recent downtrend, analysts still lean bullish, with 11 out of 18 analysts maintaining a Strong Buy rating and an average price target of $19.80, but options data suggest a bearish reality may be catching up.

Generated by AI

Topics

Of the messages about BHVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	91.67%	80.95%	3.84%
Technical Analysis	—	8.33%	10.54%	0.6%
Analysts	—	0%	1.7%	43.64%
Earnings	—	0%	4.08%	0.18%
Controversies	—	0%	2.72%	0.16%
Macro	—	0%	0%	51.57%

Earnings· Feb 25

Biohaven Pharmaceuticals ($BHVN) reported a Q4 loss of $2.32 per share, missing estimates by $0.39.
Revenue of $190.01M was up 441.1% year/year, beating consensus estimates.
The company had approximately $1.0 billion of available liquidity at the start of 2022.

Analysts· Sep 12

Biohaven Pharmaceutical's ($BHVN) price target was raised to $65 by Piper Jaffray analyst Tyler Van Buren, citing higher conviction in migraine treatments.
Morgan Stanley maintained its "Overweight" rating on Biohaven Pharmaceutical ($BHVN) with a target price of $45 per share.
Cantor Fitzgerald analysts set a price target of $57.00 for Biohaven Pharmaceutical ($BHVN), while Needham & Company LLC assigned a buy rating.

Announcements· Sep 10

Biohaven Ltd.'s ($BHVN) experimental epilepsy drug opakalim has been placed on partial clinical hold by the FDA due to findings in rodent studies.
The FDA has paused new patient enrollment in the RISE2 study, while existing patients can continue treatment, and a pivotal readout is still on track for H2 2026.
The hold is pending additional nonclinical data concerning a metabolite, and Biohaven's stock price has fallen significantly in response to the news.

Generated by AI

Community

Of the messages about BHVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	63.54%	77.63%
Newcomers	—	0%	36.46%	22.37%

Regulars· Sep 17

Biohaven's leadership has explicitly stated that they are benchmarking their anti-myostatin drug, taldefgrobep alfa, against Eli Lilly's bimagrumab efficacy profile, aiming to meet or beat established parameters for reducing body fat and increasing lean muscle mass.
Xenon's setback in psychiatry due to neuropsychiatric adverse events has effectively leveled the playing field with Biohaven in the depression market, as both companies have hit a wall in psychiatry.
If Biohaven can resolve its minor regulatory hurdle regarding rodent metabolites and present clean Phase 2/3 RISE3 data, it can position opakalim as the best-in-class alternative to Xenon's first-in-class drug, securing a massive, highly profitable cut of every dollar generated in the epilepsy market.

Newcomers· Sep 10

The FDA has placed a partial clinical hold on Biohaven's experimental epilepsy drug, opakalim, due to adverse findings in rodent studies, pausing new patient enrollment in trials.
The hold is a setback for Biohaven, which had been making progress with its epilepsy treatment and had recently received a $400 million upfront payment from SK Biopharmaceuticals for its Kv7 platform.
The hold has caused a significant decline in Biohaven's stock price, with shares falling over 13% in premarket trading and over 17% in some reports, raising concerns about the company's prospects and the potential impact on its ongoing trials.

Generated by AI

Biohaven

Social

Sep 18

Bullish· Aug 26

Bearish· Dec 26

Earnings· Feb 25

Analysts· Sep 12

Announcements· Sep 10

Regulars· Sep 17

Newcomers· Sep 10

Biohaven’s cancer drug data selected for presentation at symposium

Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?

Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven’s epilepsy drug hit with FDA clinical hold

Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN)

Also Discussed

Biohaven Ltd.

Company Information

Location

Biohaven’s cancer drug data selected for presentation at symposium

Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?

Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven’s epilepsy drug hit with FDA clinical hold

Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN)

Also Discussed

Social

Sep 18

Bullish· Aug 26

Bearish· Dec 26

Earnings· Feb 25

Analysts· Sep 12

Announcements· Sep 10

Regulars· Sep 17

Newcomers· Sep 10